Related references
Note: Only part of the references are listed.An Enhanced Hybrid Screening Approach to Identify Potent Inhibitors for the SARS-CoV-2 Main Protease From the NCI Compound Library
Shuhua G. Li et al.
FRONTIERS IN CHEMISTRY (2022)
Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
Tomas Koltai et al.
JOURNAL OF EVIDENCE-BASED INTEGRATIVE MEDICINE (2022)
The Development of 3-substituted Indolin-2-one Derivatives as Kinase Inhibitors for Cancer Therapy
Changqing Xu et al.
CURRENT MEDICINAL CHEMISTRY (2022)
Computational Prediction of Binding Affinity for CDK2-ligand Complexes. A Protein Target for Cancer Drug Discovery
Martina Veit-Acosta et al.
CURRENT MEDICINAL CHEMISTRY (2022)
Research Progress on the Drug Resistance of ALK Kinase Inhibitors
Zhen Li et al.
CURRENT MEDICINAL CHEMISTRY (2022)
Comparative studies of AlphaFold, RoseTTAFold and Modeller: a case study involving the use of G-protein-coupled receptors
Chien Lee et al.
BRIEFINGS IN BIOINFORMATICS (2022)
In-silico drug repurposing for targeting SARS-CoV-2 main protease (M-pro)
Shilpa Sharma et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2022)
Enhanced Akt/GSK-3β/CREB signaling mediates the anti-inflammatory actions of mGluR5 positive allosteric modulators in microglia and following traumatic brain injury in male mice
Shahnawaz A. Bhat et al.
JOURNAL OF NEUROCHEMISTRY (2021)
Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19
Tanuja Joshi et al.
MOLECULAR DIVERSITY (2021)
Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine
Niamh Coleman et al.
PHARMACOGENOMICS & PERSONALIZED MEDICINE (2021)
PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA
Melissa F. Adasme et al.
NUCLEIC ACIDS RESEARCH (2021)
The Role of Polyphenol (Flavonoids) Compounds in the Treatment of Cancer Cells
Abu Hazafa et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2020)
Inhibitors in AKTion: ATP-competitive vs allosteric
Glorianne Lazaro et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2020)
In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs
Zarko Gagic et al.
FRONTIERS IN CHEMISTRY (2020)
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
David J. Newman et al.
JOURNAL OF NATURAL PRODUCTS (2020)
Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours
Fei Xu et al.
CELL AND BIOSCIENCE (2020)
Biochanin A: A novel bioactive multifunctional compound from nature
Ayesha Sarfraz et al.
SCIENCE OF THE TOTAL ENVIRONMENT (2020)
A GPU-Accelerated Fast Multipole Method for GROMACS: Performance and Accuracy
Bartosz Kohnke et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2020)
A Review on Anti-Tumor Mechanisms of Coumarins
Yi Wu et al.
FRONTIERS IN ONCOLOGY (2020)
Akt in cancer: Mediator and more
Sundaramoorthy Revathidevi et al.
SEMINARS IN CANCER BIOLOGY (2019)
Akt Pathway Inhibition of the Solenopsin Analog, 2-Dodecylsulfanyl-1,-4,-5,-6-tetrahydropyrimidine
Nne E. Uko et al.
ANTICANCER RESEARCH (2019)
Flavonoids from the stems of Millettia pachyloba Drake mediate cytotoxic activity through apoptosis and autophagy in cancer cells
Wei Yan et al.
JOURNAL OF ADVANCED RESEARCH (2019)
Kinase-targeted cancer therapies: progress, challenges and future directions
Khushwant S. Bhullar et al.
MOLECULAR CANCER (2018)
Identification of natural allosteric inhibitor for Akt1 protein through computational approaches and in vitro evaluation
T. Pragna Lakshmi et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2017)
NANPDB: A Resource for Natural Products from Northern African Sources
Fidele Ntie-Kang et al.
JOURNAL OF NATURAL PRODUCTS (2017)
Maximising the potential of MKT inhibitors as anti-cancer treatments
Jessica S. Brown et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Are there physicochemical differences between allosteric and competitive ligands?
Richard D. Smith et al.
PLOS COMPUTATIONAL BIOLOGY (2017)
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
Antoine Daina et al.
SCIENTIFIC REPORTS (2017)
AKT in cancer: new molecular insights and advances in drug development
Prabhjot S. Mundi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor
Jean-Marc Lapierre et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Aschantin targeting on the kinase domain of mammalian target of rapamycin suppresses epidermal growth factor-induced neoplastic cell transformation
Cheol-Jung Lee et al.
CARCINOGENESIS (2015)
pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures
Douglas E. V. Pires et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Virtual screening strategies: Recent advances in the identification and design of anti-cancer agents
Vikash Kumar et al.
METHODS (2015)
Drugs for Allosteric Sites on Receptors
Cody J. Wenthur et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 54 (2014)
ProTox: a web server for the in silico prediction of rodent oral toxicity
Malgorzata N. Drwal et al.
NUCLEIC ACIDS RESEARCH (2014)
Computational Insights into the Inhibitory Mechanism of Human AKT1 by an Orally Active Inhibitor, MK-2206
Mohd Rehan et al.
PLOS ONE (2014)
A kinase-independent function of AKT promotes cancer cell survival
Igor Vivanco et al.
ELIFE (2014)
Toward an understanding of the sequence and structural basis of allosteric proteins
Xiaobai Li et al.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2013)
Overexpression of AKT decreases the chemosensitivity of gastric cancer cells to cisplatin in vitro and in vivo
Ling-Li Zhang et al.
MOLECULAR MEDICINE REPORTS (2013)
AfroDb: A Select Highly Potent and Diverse Natural Product Library from African Medicinal Plants
Fidele Ntie-Kang et al.
PLOS ONE (2013)
Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention
Ying Wang et al.
MOLECULAR AND CLINICAL ONCOLOGY (2013)
Discovery and Optimization of a Series of 3-(3-Phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors
Mark A. Ashwell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape
Margrith E. Mattmann et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2011)
LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery
Roman A. Laskowski et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2011)
SwissParam: A Fast Force Field Generation Tool for Small Organic Molecules
Vincent Zoete et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2011)
Open Babel: An open chemical toolbox
Noel M. O'Boyle et al.
JOURNAL OF CHEMINFORMATICS (2011)
MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
Hiroshi Hirai et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition
Wen-I Wu et al.
PLOS ONE (2010)
AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility
Garrett M. Morris et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2009)
Role of a Novel PH-Kinase Domain Interface in PKB/Akt Regulation: Structural Mechanism for Allosteric Inhibition
Veronique Calleja et al.
PLOS BIOLOGY (2009)
AKT crystal structure and AKT-specific inhibitors
CC Kumar et al.
ONCOGENE (2005)
Can correct protein models be identified?
B Wallner et al.
PROTEIN SCIENCE (2003)
Activation of the PI3K/Akt pathway and chemotherapeutic resistance
KA West et al.
DRUG RESISTANCE UPDATES (2002)
Share Paper
